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Abstract
Here, we describe an assay for the tissue content of purinogen, a highly phosphorylated labile polymer containing ATP and
phosphoglycerate found in the mitochondrial intermembrane space. We report the purinogen content (as adenine nucleotide
equivalents) of rat heart and, for the first time, of rat liver, kidney, brain and mixed skeletal muscle. The findings show that
purinogen contains very significant proportions of cell adenine nucleotides ranging from 25% of the free pool in brain and
skeletal muscle to 135% of it in kidney. The evidence that purinogen may form a controlled intracellular reservoir of
inorganic phosphate is briefly discussed. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Rapid changes in adenine content of perfused
hearts led us to propose that some storage form
must exist [1^3] and in subsequent studies, we located
a very labile rapidly turning-over oligomer of alter-
nating units of ATP and 3-phosphoglyceric acid in
rat heart [4], kidney [5] and liver [6]. Selective diges-
tion and chromatography along with 31P nuclear
magnetic resonance (NMR) and mass spectrometry
studies led us to propose a structure of 3-phospho-
[glyceroyl-Q-triphospho-5P-adenosine-3P-3-phospho]n-
glyceroyl-Q-triphospho-5P-adenosine (PG-ATP)n for
this compound for which we suggested the name oli-
gophosphoglyceroyl-ATP [7]. In subsequent work,
we have identi¢ed in liver and heart a (PG-ATP)n-
speci¢c 3P-phosphodiesterase which is found only in
the mitochondrial intermembrane space [8] tightly
complexed with its substrate [9], suggesting that
(PG-ATP)n may be exclusively located there too.
Attempts to quantitate (PG-ATP)n, which rapidly
reaches speci¢c radioactivity equilibrium with cell
[14C]ATP, led to the recognition that the (PG-
ATP)n oligomers appear to be the rapidly labelled
end-chains of a more complex polymer whose core
included additional nucleotide components [10]. We
have provisionally called this as yet incompletely
characterised polymer purinogen and devised a quan-
titative assay which involves deliberate destabilisa-
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tion of the precipitated substance and measurement
of the breakdown products by high-performance liq-
uid chromatography (HPLC). Using this assay, we
have been able to demonstrate the quantitative trans-
fer of adenosine units between free ATP and purino-
gen in perfused rat hearts [10,11]. However, the ¢nd-
ings have shown that purinogen does not act as a
storage reservoir for ATP in either moderate or se-
vere ischaemia [11]. Conversely, they support a pro-
posal that (PG-ATP)n may act as a rapidly exchange-
able pool of intracellular inorganic phosphate where
transsarcolemmal phosphate exchange is relatively
slow [10,11]. Moreover, its properties are consistent
with those expected of a labile sequestered form of
inorganic phosphate which discrepant ¢ndings from
31P NMR and extraction studies have suggested may
exist in liver and heart (see [11]).
Here, we describe the technique we have devised to
quantify tissue purinogen content, report that it can
be found additionally in brain and skeletal muscle
and provide comparative measurements for the
amounts present in some rat tissues.
2. Materials and methods
[8-14C]Adenosine (57 Ci/mol) was supplied by
Amersham International, Little Chalfont, Bucks,
UK. All other materials were as described previously
[1,3,5,10,11].
2.1. Tissue sampling and extraction
Rats (220^250 g Sprague^Dawley strain bred at
UCL) were killed by cervical dislocation. The brain
was immediately removed, rinsed in modi¢ed 4‡C
Krebs bicarbonate Ringer solution (4.8 mM KCl,
1.2 mM KH2PO4, 0.6 mM MgSO4, 1.3 mM CaCl2,
120 mM NaCl, 235.3 mM NaHCO3), pH 7, and
freeze-clamped with liquid nitrogen-cooled tongs. In
turn, the heart, liver, kidneys and hind-leg skeletal
muscle were treated in the same way: in total, the
time from tissue removal to freeze-clamping took no
more than 60 s. All subsequent operations were car-
ried out with sterile media and apparatus.
The freeze-clamped tissue was then pulverised in a
mortar pre-cooled with liquid nitrogen and subse-
quently homogenised in 3 ml of cold (310‡C) 10%
(mass/volume) trichloroacetic acid (TCA)/25% (by
volume) methanol/10 mM MgCl2 using an Ultra
Turrax homogeniser TP 18 (JankepKunkel). The
probe was washed with a further 3 ml of TCA/meth-
anol/MgCl2 and the combined homogenate centri-
fuged in a Sorvall RC-5B at 17 000 rev./min (SM-
24 rotor; gav 35 600). The supernatant containing
the soluble purine nucleotides was stored at 370‡C
and assayed by HPLC on a Waters Millenium Sys-
tem using an APS-Hypersil column (15 cmU4 mm)
developed with a linear gradient (5^400 mM) of
KH2PO4 pH 3.0. The column was calibrated using
standard solutions of the adenine nucleotides.
2.2. Estimation of purinogen
The pelletted TCA/methanol/MgCl2-insoluble ma-
terial was washed once with 10 ml cold (310‡C)
TCA/methanol/MgCl2, once with 10 ml acetone
and three times with 10 ml diethyl ether before being
dried under a stream of N2 gas. At each wash, the
pellets were resedimented by centrifugation at 10 000
rev./min in a Sorvall RC-5B (SM-24 rotor; 9774 gav).
Between 0.1 g and 0.15 g of the weighed dried extract
was resuspended in 1 ml 4 M KOH/10 mM EDTA
and placed in a water-¢lled sonic cleaning bath
(Cole-Parmer 8850; output 88 W) at room temper-
ature and agitated by sonication for 1 min and left
for 15 min with repeated sonication periods at 5 min
and 10 min. The samples were then centrifuged at
10 000 rev./min in a Sorvall RC-5B (SM-24 rotor;
9774 gav) for 10 min at 4‡C. The supernatant was
neutralised with 2 M HCl and the precipitate re-
moved by centrifugation for 2 min in an Eppendorf
Zentrifuge 3200 (8000 gav). The pellet recovered from
the Sorvall was resuspended in 0.5 ml KOH/EDTA
and the above procedure repeated. The combined
supernatants were stored at 370‡C. Before HPLC
analysis of the released purine derivatives, 200 Wl of
supernatant was ¢ltered through a 0.45 Wm Millipore
¢lter. The quantitative extraction of purinogen was
followed and purinogen breakdown products identi-
¢ed using extracts from hearts previously perfused
with [8-14C]adenosine to label the purinogen [10].
For radiochemical estimation, the HPLC column ef-
£uent was collected in 750 Wl fractions and 200 Wl
samples of these were added to 4 ml of Ecosint A
scintillation cocktail (National Diagnostics) and as-
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sayed in a Packard Tri-Carb 900CA liquid scintilla-
tion counter.
3. Results and discussion
3.1. Devising a quantitative assay for purinogen
In order to study the metabolic role of the
very labile rapidly turning-over (PG-ATP)n, we
needed a quantitative assay. Since we had shown in
both incorporation experiments [4] and by direct ex-
traction and puri¢cation [7] that this compound
rapidly appeared to reach speci¢c activity equilibri-
um with [14C]ATP, the obvious solution was to use
radioactivity measurements after radiolabelling.
However, with perfused hearts subjected to a variety
of metabolic stimuli, we were able to show convinc-
ingly that the two pools were not at radioactivity
equilibrium and that the stimuli led to changes
in the speci¢c activity of the sequestered material
[10].
Attempts to base an assay on the speci¢c phospho-
diesterase which we had found to be located in the
mitochondrial intermembrane space [8] foundered,
not only because we were unsuccessful in removing
its tightly bound substrate while keeping it native,
but also because, probably as a result of this tight
association with protein, we were unable to resolu-
bilise completely the radioactivity in the TCA/meth-
anol-precipitated material in order to make it avail-
able as substrate. We therefore devised a procedure
which depended on conditions which promoted the
breakdown of purinogen but not that of more stable
polynucleotide species also present in washed TCA/
methanol extracts: the breakdown products could
then be separated by HPLC and measured by their
absorbance at 259 nm as ATP equivalents (see [10]).
Initial extraction using alkali/EDTA only solubilised
about 50% of the precipitated radioactivity, mostly
as ATP, ADP and triphospho(5P)adenosine(3P)-3-
phosphoglycerate (PPPAdoGri) (the product of
(PG-ATP)n cleavage at its labile mixed anhydride
bond): repeated extraction using sonication to aid
dispersal of the insoluble pellet solubilised most of
the remaining radioactivity but provided a much in-
creased quantity of PPPAdoGri of much lower spe-
ci¢c radioactivity (see [10]). It yielded moreover sev-
eral labelled peaks eluting before PPPAdoGri in the
HPLC. These ‘unknowns’ have as yet not been de-
¢nitively identi¢ed but appear to be oligomers which
break down further on storage in the absence of
Mg2 to give products that co-chromatograph with
ATP, adenosine, inosine and glyceric acid (M. Sarci-
na, unpublished ¢ndings). While these unknowns
could derive from a separate rapidly labelled labile
precipitable species, these ¢ndings suggest that they
are closely associated with (PG-ATP)n although their
phosphate:purine ratio is somewhat lower at around
2:1. For these reasons, we have suggested that the
more highly labelled (PG-ATP)n may form the end-
chains of a more complex polymer of adenine nucle-
otide, phosphate and glycerate for which we have
suggested the name purinogen [10].
Fig. 1 gives an example of the HPLC pro¢le of
purinogen breakdown products obtained from a rat
heart which had previously been perfused for 10 min
with [8-14C]adenosine to label the tissue adenine nu-
cleotides [4]. Using the extraction technique de-
Fig. 1. The TCA/methanol/MgCl2-insoluble extract from a
heart was incubated with KOH/EDTA as detailed in Section
2.2. Fifty Wl of the solubilised ¢ltrate was analysed by HPLC
on APS-Hypersil as detailed in Section 2.1. The triangles de¢ne
the beginning and end of each peak whose computed area is
bounded by the solid and dotted lines. The known peaks were
identi¢ed by co-chromatography of standards. Those products
rapidly labelled by prior perfusion with [8-14C]adenosine [10]
are shaded: purinogen content is estimated as the sum of these
peaks using the molar absorbance of ATP as standard.
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scribed here (Section 2.2), solubilisation of 98^100%
of the precipitated radioactivity was obtained. Fig. 1
shows too that the breakdown products also contain
species absorbing at 259 nm which are unlabelled by
our perfusion regime and are therefore not rapidly
exchanging with free [14C]ATP as is purinogen. We
have therefore chosen to ignore them and de¢ne pu-
rinogen content as the sum of the absorbances of the
labelled species. The validity of this de¢nition is sup-
ported by the observation of the quantitative transfer
of ATP equivalents between purinogen and soluble
adenine nucleotides in perfused hearts subjected to
two di¡erent conditions which might be expected to
alter the demand for intracellular inorganic phos-
phate [11].
3.2. The purinogen content in rat tissues
A number of rat tissues were rapidly removed,
freeze-clamped and the extracts assayed for purino-
gen and the soluble adenine nucleotides as described
above and in Section 2. As might be expected, there
is some variation in the proportions of the purinogen
breakdown products from di¡erent preparations; the
sum of the adenine nucleotides represented between
19 and 32%, PPPAdoGri 16 and 27% and the un-
knowns 43 and 55% of the total. However, the
HPLC traces all conformed to the typical pattern
shown in Fig. 1 and were thus readily identi¢ed by
comparison with those from labelled hearts. Radio-
active perfusion studies similar to those with hearts
had previously shown the presence of purinogen in
kidney [5] and liver [6] but not its quantity. These
extracts showed that purinogen was also readily de-
tectable in brain and skeletal muscle and Table 1 sets
out the amounts measured in tissues from four rats
relative to the tissue protein [12] and DNA [13] con-
tent.
The use of a number of tissues from the same
animal and the consequent time di¡erence in freeze-
clamping between di¡erent tissues, however slickly
the sampling was organised, raises the prospect of
nucleotide metabolism in the brief ischemic interval.
Previous studies with ischemic hearts, livers and kid-
neys [5,6,10] have shown that in brief ischemic peri-
ods, there is some net conversion of ATP to ADP
and AMP but no change in the sum of these nucleo-
tides. In the experiments reported here, with one ex-
ception, ATP represented between 57% and 77% of
the adenine nucleotide content (data not given): the
exception was brain which, although sampled ¢rst,
had equal amounts of ATP and AMP at 40% of
the total. In the case of purinogen, we have shown
with perfused hearts that neither severe reversible (20
min) or irreversible (40 min) ischemia causes any
change in the measured purinogen content from
that in controls [11] and in line with this, the heart
purinogen content in Table 1 compares well with
previous estimates [10,11] using a mean protein con-
tent of 140 mg/g wet tissue. It seems reasonable
therefore, at least initially, to expect that a brief pe-
riod of ischemia will have no e¡ect on the purinogen
content of other rat tissues.
There is no obvious correlation between the con-
tents of free nucleotides and those in purinogen in
the di¡erent tissues. The ¢ndings do show, however,
that substantial proportions of tissue nucleotides are
bound up in the polymer. In brain and mixed skeletal
muscle, the purinogen nucleotide content amounts to
a quarter of that in free adenine nucleotide, while in
heart it is 60% and in liver equal to that of the free
adenine nucleotides. Relatively the greatest propor-
Table 1
The contents of purinogen and of free adenine nucleotides in some rat tissues
Purinogen (nmol/mg protein) 4 AN Purinogen (nmol/mg DNA) 4 AN
Liver 14.4 þ 1.5 14.9 þ 3.5 1 204 þ 74 1 209 þ 281
Heart 10.96 þ 0.55 18.9 þ 1.2 647 þ 33 1 115 þ 73
Brain 5.69 þ 0.78 23.5 þ 5.1 677 þ 62 2 769 þ 439
Kidney 19.97 þ 0.99 14.5 þ 1.7 951 þ 110 726 þ 62
Skeletal muscle 11.2 þ 1.8 46.2 þ 2.8 3 571 þ 574 16 600 þ 1 100
4 AN denotes the sum of the contents of ATP+ADP+AMP in the soluble tissue extract.
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tion is in kidney which has 35% more nucleotide in
purinogen than in the free state. For comparison, the
adenine nucleotide content of rat heart total RNA is
about 30% of that in free nucleotides [1,14].
From these ¢ndings, the potential for rapidly turn-
ing-over purinogen to augment the adenine nucleo-
tide pool would appear to be considerable: and its
failure to do so in severely ischemic rat hearts when
there is substantial conversion of ATP to oxidised
purines [11] is all the more surprising. By contrast,
we have found that removing inorganic phosphate
from heart perfusion bu¡er and providing glucose
to a heart previously perfused without nutrient to
deplete endogenous supplies of glycogen and fatty
acid caused net transfer of nucleotide between free
ATP and purinogen [10,11]. These treatments might
be expected to alter the demand for intracellular in-
organic phosphate and have led to the suggestion
[11] that the four phosphates per purine base present
in (PG-ATP)n may provide a controlled reservoir of
intracellular phosphate, which a number of 31P
NMR studies have suggested may exist (see [11] for
further discussion). Further investigation is needed to
examine this proposition; but it could be consistent
with the presence of a relatively large purinogen con-
tent in kidney which has a major role in the control
and transport of body inorganic phosphate.
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